Austrian Single Family Office Successfully Sells HSO Health


Published: 2025-05-18 Source: Author:
Austrian Single Family Office Successfully Sells HSO Health

Finance Image

Vienna-based probiotics company HSO Health Care is sold to Danish biotech firm Chr. Hansen by Alexander Schütz and Helmut Essl. Alexander Schütz was holding HSO through his family office, which is an active private equity investor in Austria.HSO Health Care: Probiotics for WomenHSO was founded in 2007 by Helmut Essl. The company is doing research in the probiotics field. Probiotics are microorganisms that are claimed to provide health benefits. HSO’s main product is the patented Astarte products which are sold in several countries. In Switzerland, the product is called Biotics-fem and marketed by the Burgerstein – Antistress AG, in the United States the products are marketed by Jarrow and iHealth as Jarro-Dophilus, Azo or Culturelle probiotics. Now, Danish stock-listed biotech company Chr. Hansen is acquiring HSO and its patented Astarte product.Alexander Schütz Vienna-based Single Family Office as private equity investor was an investor in HSO. Schütz is the founder and CEO of the Austrian C-Quadrat Investment group with 8 billions of assets under management. Through his family office, Schütz invests in startups, private equity deals and real estate. Other investments include biotech company ATAI Life Sciences, ADC Therapeutics, Cyberfinancials GmbH or Cyan Digital Security.SourceYou might like these family office articlesRelevant family office lists Rated 5.00 out of 5 €399,99 including VAT €4,99 including VAT Rated 5.00 out of 5 €699,99 including VAT Rated 4.67 out of 5 €1.499,99 including VAT

User Comments1. Nathan W.: Comment sample 1...2. William Garcia: Comment sample 2...3. Ella Adams: Comment sample 3...4. Owen E.: Comment sample 4...5. Cook, Owen: Comment sample 5...Editor's NoteThis article was refined for clarity, structure, and user experience.

Finance Image

(Editors: admin)

Disclaimer & Copyright Notice:
This article is edited and compiled by the editorial team at WealthShield Asia based on publicly available information. It is intended for informational purposes only and does not constitute legal, financial, or investment advice.

We respect intellectual property rights. If you believe that any part of this article infringes upon your copyright or other legal rights, please contact us at admin@wealthshield.asia. We will promptly review and remove the content if necessary.

All rights reserved. Unauthorized reproduction or redistribution is prohibited.